--- title: "Legend Biotech Sets September 24, 2026 AGM With Expanded Equity Plan on Agenda" type: "News" locale: "en" url: "https://longbridge.com/en/news/296267145.md" description: "Legend Biotech has scheduled its Annual General Meeting for September 24, 2026. Key agenda items include adopting 2025 financial statements, re-electing directors, and approving an amended restricted share unit plan adding 19.1 million shares for equity compensation. The meeting aims to reinforce governance stability and management incentives under interim CEO Alan Bash." datetime: "2026-08-18T20:28:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296267145.md) - [en](https://longbridge.com/en/news/296267145.md) - [zh-HK](https://longbridge.com/zh-HK/news/296267145.md) generator: "portal-rs" --- # Legend Biotech Sets September 24, 2026 AGM With Expanded Equity Plan on Agenda ### Summer Sale - Claim 70% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Legend Biotech ( (LEGN) ) has issued an update. Legend Biotech has called its Annual General Meeting of shareholders for September 24, 2026, at its Bridgewater, New Jersey headquarters, with voting rights set for holders of record as of August 17, 2026. The agenda includes reception of audited 2025 financial statements, ratification of Ernst & Young LLP as auditor for 2026, re-election of four Class III directors to new three-year terms, and approval of an amended restricted share unit plan that would add 19.1 million ordinary shares for equity-based compensation, underscoring continued emphasis on governance stability and incentives for management and staff. Shareholders and ADS holders will vote by proxy or instruction through JPMorgan Chase Bank, N.A., with resolutions decided by poll under a simple majority, reflecting customary U.S. and international capital market practices. The proposed equity plan expansion signals Legend Biotech’s intention to maintain competitive talent retention and alignment of management interests with shareholders, while the board’s recommendations on all agenda items aim to reinforce continuity in oversight during a period when the company remains led by interim chief executive officer Alan Bash. The most recent analyst rating on (LEGN) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page. **Spark’s Take on LEGN Stock** According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral. The score is held back primarily by ongoing negative cash flow and a weak technical setup (price below key moving averages with negative MACD). Offsetting these risks, the earnings call points to strong CARVYKTI sales momentum and management’s guidance for sustained adjusted profitability in 2H 2026, while valuation remains constrained by negative earnings and no dividend support. To see Spark’s full report on LEGN stock, click here. **More about Legend Biotech** Legend Biotech Corporation is a biotechnology company focused on developing and commercializing cell therapies, operating from its principal executive offices in Bridgewater, New Jersey. The company is listed in the United States as a foreign private issuer and has a broad shareholder base that includes ordinary share investors and holders of American depositary shares represented by JPMorgan Chase Bank. **Average Trading Volume:** 2,710,315 **Technical Sentiment Signal:** Sell **Current Market Cap:** $3.95B See more data about LEGN stock on TipRanks’ Stock Analysis page. ### Related Stocks - [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [Legend Biotech CEO Alan Bash joins Morgan Stanley Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297649230.md) - [Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?](https://longbridge.com/en/news/296957090.md) - [TrustFinance Community Choice Awards 2026 Opens Global Voting](https://longbridge.com/en/news/297658492.md) - [Vantiva announces combined shareholders meeting](https://longbridge.com/en/news/297806817.md) - [Oculus announces annual shareholder meeting](https://longbridge.com/en/news/297894904.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**